Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
AKNA (AT-hook transcription factor) is an intranuclear protein with an AT-hook motif. The AT-hook protein was first discovered in the mammalian non-histone chromosomal high-mobility group protein HMG-I/Y. The AT-hook protein family mainly includes the high mobility group protein (HMG) family. Human AKNA is a transcription factor with an AT-hook motif at the N-terminus and C-terminus, while the mouse AKNA has an AT-hook motif at the N-terminus and an AT-hook-like motif (ALM) at the C-terminus. The human AKNA gene is 63bp in length and contains 24 exons and 2 polyadenylation sites encoding 9 different transcripts. Human AKNA also has three PEST (proline-glutamate-serine-threonine) regions, and the PEST sequence is closely related to the stability of nuclear proteins, so AKAN can be stably present in the nucleus.
The main structural feature of the AT-hook protein motif is a small motif centered on the arginine-glycine-arginine-valine (RGRP) four amino acid residues, so the AT-hook protein motif is also known as RGRP motif. AKNA consists of a 9 amino acid domain with an amino acid sequence of RTRGRPADS, which is consistent with the AT-hook protein DNA binding motif. At the same time, this short conserved amino acid sequence is essential for the localization of the AT-hook protein. The AT-hook protein combines with the AT-base-rich DNA region through an amino acid motif to coordinate the transcription of the promoter by modifying the structure of the DNA to increase the activity of the promoter that binds to the transcription factor.
Martíneznava et al. found that the transcription factor AKNA is mainly expressed on B lymphocytes, T lymphocytes, natural killer cells and stem cells, and plays a crucial role in the immune response. In recent years, studies have found that knocking out the AKNA gene can lead to severe lung injury, neutrophil-mediated inflammatory response, and fetal growth retardation. In addition, loss of AKNA function directly leads to cervical neoplastic lesions. It can be seen that AKNA is closely related to human health and plays a decisive role in the occurrence and development of diseases.
The Biological Function of AKNA
Inducing Tumorigenic Transformation
The relationship between AKNA and neoplastic disease is a hot topic in current research. Qin et al. reported that the high mobility group protein A1 (HMGA1) belonging to the AT-hook protein family is overexpressed in breast cancer, bladder cancer, and brain cancer. This overexpression activates the inflammatory pathway and promotes carcinogenic transformation. Therefore, it is speculated that AKNA may have a similar effect to HMGA1. It has been reported that the 9q32 region where AKNA is located on the human chromosome contains a cervical cancer susceptibility site. The AT-hook domain single nucleotide polymorphism (SNP) on the transcription factor AKNA increases the risk of cervical cancer, and also indicates that loss of AKNA function can potentially increase human papillomavirus (HPV)-mediated inflammation, thereby promoting cervical neoplastic lesions. The expression level of AKNA is also related to the polymorphism of the promoter associated with cervical cancer.
Chronic inflammation is a common and important factor in the pathogenesis of tumors. It develops into cancer under the action of toxicological factors or under inflammatory pathological conditions. Helicobacter pylori can cause gastric cancer, and the gastroesophageal reflux disease department causes malignant adenoma. Therefore, there is an upstream and downstream relationship between transcription factor AKNA, inflammation and cervical cancer. Removal of AKNA can increase HPV-mediated inflammation, which can induce cervical cancer, and cervical cancer-related promoters in turn also affect the expression level of AKNA.
Participate in the Occurrence of Inflammatory Reactions
Acute and neoplastic diseases can lead to neutrophil-mediated inflammation, and the AKNA gene may be one of the decisive risk factors. Human AKNA is encoded by a single gene located in the sensitive region of the chromosome fragile site 9q32, whereas dysfunctional mutations in fragile sites often lead to inflammatory and neoplastic diseases. The mouse AKNA gene is located on the fragile site of the FRA4C2 fragility site, which is frequently altered in inflammatory responses and cancer. AKNA is closely related to inflammatory responses and tumor formation. When the AKNA gene is knocked out, it can cause death and neutrophil inflammatory response in newborn mice, while protecting the body from the harmful effects of inflammation when restoring AKNA function. Thus, AKNA plays an important role in the inflammatory response.
Figure 1. AKNA in the mechanism of T-2 toxin-mediated growth inhibition. (Liu, et al. 2016).
Functional Regulation of AKNA
AKNA is an important transcription factor regulating the expression of key receptor-ligands, which up-regulates the expression of CD40 on the surface of T cells and B cells, and has important physiological significance during the secondary immune response. In the experiment of knocking out the AKNA gene leading to severe pneumonia, it was found that the expression levels of matrix metalloproteinase-9 (MMP-9), interleukin-1β (IL-1β), interferon-γ (IFN-γ), antibacterial peptide protein (CRAMP) ), neutrophil (NGP) and S100A9 genes are increased. In particular, MMP-9 expression was three times higher in wild-type mice in mice knocked out of the AKNA gene because AKNA inhibited the expression of the MMP-9 promoter-driven gene.
The MMP-9, IL-1β, IFN-γ, NGP, CRAMP and S100A9 promoters have an AT base sequence that binds to the transcription factor AKNA and satisfies the conditions for binding to the AT-hook protein. NGP is an important component of neutrophils and is involved in neutrophil-mediated lung inflammation. CRAMP is an angiogenesis-related protein that is involved in the transfer of neutrophils after activation by MMP, leading to the infiltration of neutrophils in the lungs.
S100A9 is a member of the calcium-binding protein family whose activity is regulated by the proteolytic process of MMP-9 and is involved in the enrichment of neutrophils in the microenvironment of the lung inflammation. MMP-9 belongs to neutrophil collagenase, which activates IL-1β expression, while IL-1β can aggregate neutrophils into the lungs to cause lung damage. MMP-9 is involved in lung injury and inflammatory response, and the MMP gene (MMP-2, MMP-9, MMP-13) is also a downstream substance of the AT-hook protein HMGA1, suggesting that it may also be a downstream substance of the transcription factor AKNA. AKNA can promote the development of inflammation, and inflammation is often an important precancerous lesion of many cancers. However, the upstream and downstream relationship and mechanism of AKNA transcription factors are still unclear and need further study.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.